Logo Logo

Category Archives: "Partners"

  1. Home
  2. CMSC PR
  3. Page 5
Mar 03, 2020
Multiple sclerosis and COVID-19 registry
CMSC PR, Partners
Dear Colleagues and Clients:  We know you are interested in what happens to people with MS and related diseases who develop [...]
Elizabeth Porco
Read More
...138
0
Feb 27, 2020
Please read: Coronavirus and multiple sclerosis statement
Partners
The MS International Federation (also known as MSIF) has compiled information and a video (available here) which sufficiently [...]
Elizabeth Porco
Read More
...113
0
Dec 01, 2019
Results for Genentech’s Satralizumab in Neuromyelitis Optica Spectrum
INforMS, Partners
Satralizumab demonstrated robust efficacy, sustained for 144 weeks, in significantly reducing the risk of relapse in combination with [...]
Elizabeth Porco
Read More
...123
0
Nov 26, 2019
NeurologyLive™ adds CMSC to its Strategic Alliance Partnership program
INforMS, Partners
CRANBURY, N.J.--(BUSINESS WIRE)--NeurologyLive™, a multimedia platform dedicated to providing health care professionals treating [...]
Elizabeth Porco
Read More
...124
0
Sep 17, 2019
EMD Serono initiates pivotal Phase III program for investigational Evobrutinib in RMS
INforMS, Partners
ROCKLAND, Mass., Sept. 10, 2019 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. [...]
Elizabeth Porco
Read More
...120
0
Sep 12, 2019
Genentech presents new six-year Ocrevus (Ocrelizumab) data
INforMS, Partners
Post-hoc analysis from a Phase III open-label extension study showed a 42% reduction in the risk of PPMS patients needing a wheelchair [...]
Elizabeth Porco
Read More
...118
0
Sep 11, 2019
Genentech’s Satralizumab significantly reduced relapse risk
INforMS, Partners
Pivotal Phase III SAkuraStar study shows 55% reduction in the risk of relapse for satralizumab monotherapy versus placebo presented at [...]
Elizabeth Porco
Read More
...122
0
Sep 09, 2019
Genentech presents new Ocrevus (Ocrelizumab) biomarker data
INforMS, Partners
Blood neurofilament light chain (NfL) levels were significantly lowered following Ocrevus treatment in analyses of Phase III studies in RMS [...]
Elizabeth Porco
Read More
...113
0
Sep 03, 2019
Press release – Genentech to present piviotal data at ECTRIMS
INforMS, Partners
Investigational medicine satralizumab significantly reduces the risk of relapse in pivotal SAkuraStar monotherapy study for neuromyelitis [...]
Elizabeth Porco
Read More
...106
0
Aug 07, 2019
Rutgers Health leading program to support multiple sclerosis children
INforMS, Partners
Rutgers Health is leading the Pediatric Multiple Sclerosis and Demyelinating Diseases Program, the only program in the state of New [...]
Elizabeth Porco
Read More
...111
0
  • (201) 487-1050
  • 3 University Plz Dr Ste 116, Hackensack, NJ 07601
  • info@mscare.org

Upcoming Testing Periods

WINTER 2024 TESTING PERIOD

Application Deadline: December 6th, 2023

First Day of Testing: Saturday, January 6th, 2024

Last Day of Testing: Saturday, January 20th, 2024

SUMMER 2024 TESTING PERIOD

Application Deadline: May 1st, 2024

First Day of Testing: Saturday, June 1st, 2024

Last Day of Testing: Saturday, June 15th, 2024

Resources

Visit PTC to download a PDF version of the Handbook. Candidates can also apply online.

For more information:

Professional Testing Corporation http://www.ptcny.com/

  • 212-356-0660
  • 1350 Broadway, 17th Floor, New York, NY 10018

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us





I have a question about

First

Last




Feel Free To contact Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam molestie, tellus id pellen tesque feugiat, sem sem cursus orci, a placerat ante ante nec massa. consectetuer adipiscing elit.

+1-222-333-4444

New York, NY 10123 USA

Mon - Sat 9:00 AM